688117 圣诺生物
已收盘 05-18 15:00:00
资讯
新帖
简况
圣诺生物(688117)披露2025年年度股东会决议公告,5月18日股价下跌0.31%
证券之星 · 05-18 18:28
圣诺生物(688117)披露2025年年度股东会决议公告,5月18日股价下跌0.31%
每周股票复盘:圣诺生物(688117)召开2025年度业绩说明会
证券之星 · 05-17 03:03
每周股票复盘:圣诺生物(688117)召开2025年度业绩说明会
圣诺生物(688117)披露召开2025年度暨2026年第一季度业绩说明会公告,5月13日股价下跌1.68%
证券之星 · 05-13
圣诺生物(688117)披露召开2025年度暨2026年第一季度业绩说明会公告,5月13日股价下跌1.68%
每周股票复盘:圣诺生物(688117)2025年净利增215.70%
证券之星 · 05-10
每周股票复盘:圣诺生物(688117)2025年净利增215.70%
圣诺生物(688117)披露2025年年度股东会会议资料,5月7日股价上涨1.22%
证券之星 · 05-07
圣诺生物(688117)披露2025年年度股东会会议资料,5月7日股价上涨1.22%
30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧
股市必读:圣诺生物年报 - 第四季度单季净利润同比增长546.55%
证券之星 · 04-27
股市必读:圣诺生物年报 - 第四季度单季净利润同比增长546.55%
每周股票复盘:圣诺生物(688117)股东户数增18.89%,净利升40.84%
证券之星 · 04-26
每周股票复盘:圣诺生物(688117)股东户数增18.89%,净利升40.84%
图解圣诺生物年报:第四季度单季净利润同比增长546.55%
证券之星 · 04-24
图解圣诺生物年报:第四季度单季净利润同比增长546.55%
圣诺生物最新公告:全资子公司取得药品生产许可证
证券之星 · 03-30
圣诺生物最新公告:全资子公司取得药品生产许可证
每周股票复盘:圣诺生物(688117)部分高管减持期满未减持
证券之星 · 03-29
每周股票复盘:圣诺生物(688117)部分高管减持期满未减持
圣诺生物(688117.SH):利那洛肽原料药获得上市申请批准通知书
智通财经网 · 03-04
圣诺生物(688117.SH):利那洛肽原料药获得上市申请批准通知书
每周股票复盘:圣诺生物(688117)2025年净利增231.49%
证券之星 · 03-01
每周股票复盘:圣诺生物(688117)2025年净利增231.49%
圣诺生物(688117)披露2025年度业绩快报,2月27日股价下跌1.59%
证券之星 · 02-27
圣诺生物(688117)披露2025年度业绩快报,2月27日股价下跌1.59%
圣诺生物(688117.SH)部分产品拟中选新一轮接续采购
智通财经 · 02-11
圣诺生物(688117.SH)部分产品拟中选新一轮接续采购
BFB HEALTH与圣诺生物签署战略合作协议
人民财讯 · 01-22
BFB HEALTH与圣诺生物签署战略合作协议
每周股票复盘:圣诺生物(688117)2025净利预增204.42%至280.53%
证券之星 · 01-18
每周股票复盘:圣诺生物(688117)2025净利预增204.42%至280.53%
净利润预增超200%,圣诺生物借GLP-1减肥赛道大口“吃肉”
华夏时报网 · 01-16
净利润预增超200%,圣诺生物借GLP-1减肥赛道大口“吃肉”
圣诺生物:预计2025年全年归属净利润盈利1.52亿元至1.9亿元
证券之星 · 01-15
圣诺生物:预计2025年全年归属净利润盈利1.52亿元至1.9亿元
1月7日圣诺生物涨7.28%,华商智能生活灵活配置混合A基金重仓该股
证券之星 · 01-07
1月7日圣诺生物涨7.28%,华商智能生活灵活配置混合A基金重仓该股
暂无数据
公司概况
公司名称:
成都圣诺生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-06-03
主营业务:
成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是醋酸奥曲肽注射液、注射用生长抑素、卡贝缩宫素注射液、醋酸阿托西班注射液、依替巴肽注射液、注射用胸腺法新、注射用胸腺五肽、注射用恩夫韦肽、艾替班特注射液、泊沙康唑注射液、醋酸加尼瑞克注射液、艾塞那肽注射液。
发行价格:
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":35.67,"timestamp":1779087600000,"preClose":35.78,"halted":0,"volume":1453332,"delay":0,"changeRate":-0.0031,"floatShares":157000000,"shares":157000000,"eps":1.1257,"marketStatus":"已收盘","change":-0.11,"latestTime":"05-18 15:00:00","open":35.8,"high":35.88,"low":35.13,"amount":51574200,"amplitude":0.021,"askPrice":35.69,"askSize":30,"bidPrice":35.67,"bidSize":21,"shortable":0,"etf":0,"ttmEps":1.1257,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"adjPreClose":35.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":39.36,"lowLimit":32.2,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":157385978,"isCdr":false,"pbRate":4.99,"roa":"--","peRate":31.68695,"roe":"6.08%","epsLYR":1,"committee":-0.261905,"marketValue":5614000000,"turnoverRate":0.0092,"status":1,"afterMarket":{"amount":0,"volume":0,"close":35.67,"buyVolume":0,"sellVolume":0,"time":1779089637558,"indexStatus":"已收盘 05-18 15:30:00","preClose":35.78},"floatMarketCap":5614000000},"requestUrl":"/m/hq/s/688117/tweets","defaultTab":"tweets","newsList":[{"id":"2636228060","title":"圣诺生物(688117)披露2025年年度股东会决议公告,5月18日股价下跌0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636228060","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636228060?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:28","pubTimestamp":1779100100,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘,圣诺生物报收于35.67元,较前一交易日下跌0.31%,最新总市值为56.14亿元。该股当日开盘35.8元,最高35.88元,最低35.13元,成交额达5157.42万元,换手率为0.92%。近日,圣诺生物发布《2025年年度股东会决议公告》。所有议案均获通过,无否决议案。会议表决方式和程序合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800029558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064387","title":"每周股票复盘:圣诺生物(688117)召开2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064387","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636064387?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:03","pubTimestamp":1778958191,"startTime":"0","endTime":"0","summary":"本周关注点来自公司公告汇总:圣诺生物将于2026年5月20日召开2025年度暨2026年第一季度业绩说明会。来自公司公告汇总:北京海润天睿律师事务所确认圣诺生物2025年年度股东会表决程序及结果合法有效。公司公告汇总关于召开2025年度暨2026年第一季度业绩说明会的公告成都圣诺生物科技股份有限公司将于2026年5月20日10:00-11:00通过上证路演中心网络文字互动方式召开2025年度暨2026年第一季度业绩说明会,介绍公司2025年年度报告及2026年第一季度报告的相关内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635985200","title":"圣诺生物(688117)披露召开2025年度暨2026年第一季度业绩说明会公告,5月13日股价下跌1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635985200","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635985200?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:51","pubTimestamp":1778665883,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘,圣诺生物报收于36.82元,较前一交易日下跌1.68%,最新总市值为57.95亿元。圣诺生物于近日发布《关于召开2025年度暨2026年第一季度业绩说明会的公告》。公告显示,公司将于2026年5月20日10:00-11:00通过上证路演中心网络文字互动方式召开业绩说明会,介绍公司2025年年度报告及2026年第一季度报告的相关内容。投资者可于2026年5月13日至5月19日16:00前通过上证路演中心提问预征集栏目或公司邮箱提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634414532","title":"每周股票复盘:圣诺生物(688117)2025年净利增215.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634414532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634414532?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:22","pubTimestamp":1778350933,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,圣诺生物报收于36.75元,较上周的37.41元下跌1.76%。本周,圣诺生物5月6日盘中最高价报38.41元。圣诺生物当前最新总市值57.84亿元,在化学制药板块市值排名93/150,在两市A股市值排名3223/5200。董事会全年召开5次会议,执行了股东会各项决议,规范运作公司治理,完成信息披露、投资者关系管理等工作。2026年公司将聚焦多肽医药领域,推进产能扩张、市场拓展、研发创新及人才建设。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633812667","title":"圣诺生物(688117)披露2025年年度股东会会议资料,5月7日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633812667","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633812667?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:42","pubTimestamp":1778164935,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,圣诺生物报收于37.23元,较前一交易日上涨1.22%,最新总市值为58.59亿元。该股当日开盘37.06元,最高37.77元,最低36.58元,成交额达1.3亿元,换手率为2.22%。近日,圣诺生物披露《2025年年度股东会会议资料》。公告显示,成都圣诺生物科技股份有限公司2025年度实现营业收入741,455,412.91元,同比增长62.57%;归属于公司所有者的净利润157,924,373.41元,同比增加215.70%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉:有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日,A股医药板块迎来一季度财报密集披露期,包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0191","BK0216","BK0071","BK0196","BK0183","301281","688621","688117","06978","BK0188","BK0028","300723","BK1161","002550","BK0250","BK0209","LU2328871848.SGD","BK0187","BK0132","BK0175","BK0239","000950","LU1969619763.USD","600216","000963","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630433635","title":"股市必读:圣诺生物年报 - 第四季度单季净利润同比增长546.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630433635","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630433635?lang=zh_cn&edition=full","pubTime":"2026-04-27 02:59","pubTimestamp":1777229948,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告圣诺生物2025年年报显示,当年度公司主营收入7.41亿元,同比上升62.57%;归母净利润1.58亿元,同比上升215.7%;扣非净利润1.65亿元,同比上升261.31%;其中2025年第四季度,公司单季度主营收入2.21亿元,同比上升87.2%;单季度归母净利润3091.42万元,同比上升546.55%;单季度扣非净利润3872.76万元,同比上升581.5%;负债率45.33%,投资收益195.53万元,财务费用1695.85万元,毛利率57.65%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630801295","title":"每周股票复盘:圣诺生物(688117)股东户数增18.89%,净利升40.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630801295","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630801295?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:52","pubTimestamp":1777143129,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,圣诺生物报收于38.68元,较上周的36.86元上涨4.94%。本周,圣诺生物4月24日盘中最高价报39.33元。圣诺生物当前最新总市值60.88亿元,在化学制药板块市值排名90/150,在两市A股市值排名2995/5200。本周关注点股本股东变化:股东户数较12月31日增加18.89%。股本股东变化股东户数变动截至2026年3月31日,公司股东户数为1.0万户,较12月31日增加1591.0户,增幅18.89%;户均持股数量由1.87万股降至1.57万股,户均持股市值为55.62万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629545178","title":"图解圣诺生物年报:第四季度单季净利润同比增长546.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629545178","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629545178?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:42","pubTimestamp":1776966161,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物2025年年报显示,当年度公司主营收入7.41亿元,同比上升62.57%;归母净利润1.58亿元,同比上升215.7%;扣非净利润1.65亿元,同比上升261.31%;其中2025年第四季度,公司单季度主营收入2.21亿元,同比上升87.2%;单季度归母净利润3091.42万元,同比上升546.55%;单季度扣非净利润3872.76万元,同比上升581.5%;负债率45.33%,投资收益195.53万元,财务费用1695.85万元,毛利率57.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400004203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313018","title":"圣诺生物最新公告:全资子公司取得药品生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623313018?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:40","pubTimestamp":1774863655,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称,全资子公司眉山汇龙药业科技有限公司近日取得四川省药品监督管理局核发的《药品生产许可证》,分类码为Dh,生产范围限于原料药(仅限注册申报使用),有效期至2031年3月25日。该资质为眉山汇龙首次取得,标志着其原料药已具备合规生产条件,符合行业监管要求,有利于公司保持稳定生产能力、提升核心竞争力,对未来发展有积极推动作用。但医药行业生产销售受政策、市场等多因素影响,存在不确定性,提醒投资者注意风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338871","title":"每周股票复盘:圣诺生物(688117)部分高管减持期满未减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623338871?lang=zh_cn&edition=full","pubTime":"2026-03-29 02:58","pubTimestamp":1774724288,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,圣诺生物报收于33.78元,较上周的34.75元下跌2.79%。本周,圣诺生物3月23日盘中最高价报34.49元。公司公告汇总部分董事、高级管理人员减持股份结果暨未实施减持的公告成都圣诺生物科技股份有限公司于2025年12月1日披露部分董事、高级管理人员减持股份计划,副总经理马中刚、董事兼副总经理伍利拟各自减持不超过18,816股,减持期间为2025年12月23日至2026年3月22日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616580787","title":"圣诺生物(688117.SH):利那洛肽原料药获得上市申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616580787","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616580787?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:38","pubTimestamp":1772613484,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)发布公告,公司全资子公司成都圣诺生物制药有限公司于近日收到国家药品监督管理局签发的关于利那洛肽原料药的《化学原料药上市申请批准通知书》。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/18.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺生物(688117.SH):利那洛肽原料药获得上市申请批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616481608","title":"每周股票复盘:圣诺生物(688117)2025年净利增231.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616481608","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616481608?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:19","pubTimestamp":1772299148,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,圣诺生物报收于38.32元,较上周的38.66元下跌0.88%。本周关注点来自业绩披露要点:圣诺生物2025年归属净利润同比增长231.49%。业绩披露要点圣诺生物近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润盈利1.658亿元,同比增长231.49%。公司公告汇总成都圣诺生物科技股份有限公司发布2025年度业绩快报,营业总收入741,343,445.99元,同比增长62.55%;营业利润200,844,661.43元,同比增长223.63%;归属于母公司所有者的净利润165,823,888.08元,同比增长231.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614303854","title":"圣诺生物(688117)披露2025年度业绩快报,2月27日股价下跌1.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614303854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614303854?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:14","pubTimestamp":1772201660,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,圣诺生物报收于38.32元,较前一交易日下跌1.59%,最新总市值为60.31亿元。该股当日开盘38.66元,最高38.94元,最低38.1元,成交额达1.32亿元,换手率为2.18%。近日,成都圣诺生物科技股份有限公司发布2025年度业绩快报,营业总收入741,343,445.99元,同比增长62.55%;营业利润200,844,661.43元,同比增长223.63%;归属于母公司所有者的净利润165,823,888.08元,同比增长231.49%。扣除非经常性损益后的净利润同比增长278.52%。公司总资产193,712.57万元,较期初增长17.55%;股本因资本公积金转增增至157,385,978股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610984691","title":"圣诺生物(688117.SH)部分产品拟中选新一轮接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610984691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610984691?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:20","pubTimestamp":1770798016,"startTime":"0","endTime":"0","summary":"智通财经APP讯, 圣诺生物(688117.SH)发布公告,公司全资子公司成都圣诺生物制药有限公司于近日参与了国家组织的第一批至第八批国家集采药品新一轮接续采购工作,本次接续采购是国家组织集采的化学药品首次开展全国范围统一接续,根据《国家组织集采药品协议期满品种接续采购拟中选结果表》(LC-YPJX-2026-1)显示,公司产品醋酸奥曲肽注射剂(第七批中选)、醋酸阿托西班注射剂(第八批中选)、生长抑素注射剂(第八批中选)与公司新中选产品胸腺法新注射剂、依替巴肽注射剂共同拟中选本次新一轮接续采购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605977524","title":"BFB HEALTH与圣诺生物签署战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2605977524","media":"人民财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605977524?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:29","pubTimestamp":1769092149,"startTime":"0","endTime":"0","summary":"人民财讯1月22日电,1月22日,港股上市公司财讯传媒集团有限公司(00205.HK)正式更名为“BFBHealthLimited”,中文股票简称由“财讯传媒”更改为“BFBHEALTH”。此外,当日,BFBHEALTH宣布与A股科创板上市公司圣诺生物签署战略合作协议,双方将在生物健康领域展开深度合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627744480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604928275","title":"每周股票复盘:圣诺生物(688117)2025净利预增204.42%至280.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928275","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928275?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:55","pubTimestamp":1768672510,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,圣诺生物报收于42.64元,较上周的44.36元下跌3.88%。本周,圣诺生物1月12日盘中最高价报46.5元。本周关注点业绩披露要点:圣诺生物预计2025年归母净利润同比增长204.42%至280.53%。公司公告汇总成都圣诺生物科技股份有限公司预计2025年度实现归属于母公司所有者的净利润15,228.31万元至19,035.38万元,同比增长204.42%至280.53%;扣除非经常性损益后的净利润为14,872.70万元至18,590.88万元,同比增长226.07%至307.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603986959","title":"净利润预增超200%,圣诺生物借GLP-1减肥赛道大口“吃肉”","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986959","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986959?lang=zh_cn&edition=full","pubTime":"2026-01-16 19:02","pubTimestamp":1768561320,"startTime":"0","endTime":"0","summary":"2026年1月15日晚间,成都圣诺生物科技股份有限公司发布2025年度业绩预告。供需矛盾凸显 GLP-1类药物减肥适应症的突破,成为引爆全球市场的关键,推动其需求从医疗场景延伸至消费市场。 综合来看,圣诺生物2025年的业绩高增长,是其精准抓住GLP-1全球供应链机遇的结果,具有明显的周期性和结构性特征。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-16/doc-inhhnzat5490220.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-16/doc-inhhnzat5490220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["GLP","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603605611","title":"圣诺生物:预计2025年全年归属净利润盈利1.52亿元至1.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603605611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603605611?lang=zh_cn&edition=full","pubTime":"2026-01-15 18:00","pubTimestamp":1768471237,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物发布业绩预告,预计2025年全年归属净利润盈利1.52亿元至1.9亿元。圣诺生物2025年三季报显示,前三季度公司主营收入5.2亿元,同比上升53.96%;归母净利润1.27亿元,同比上升123.03%;扣非净利润1.26亿元,同比上升134.97%;其中2025年第三季度,公司单季度主营收入1.83亿元,同比上升31.43%;单季度归母净利润3805.35万元,同比上升8.23%;单季度扣非净利润3659.84万元,同比上升5.98%;负债率45.95%,投资收益105.57万元,财务费用1111.45万元,毛利率56.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601827199","title":"1月7日圣诺生物涨7.28%,华商智能生活灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601827199","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601827199?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:33","pubTimestamp":1767771228,"startTime":"0","endTime":"0","summary":"证券之星消息,1月7日圣诺生物涨7.28%,收盘报41.25元,换手率5.48%,成交量8.63万手,成交额3.47亿元。重仓圣诺生物的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级1家,增持评级1家。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共6家,其中持有数量最多的公募基金为华商基金的华商智能生活灵活配置混合A。华商智能生活灵活配置混合A目前规模为2.37亿元,最新净值2.017,较上一交易日下跌0.05%,近一年上涨78.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700017950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779132025129,"stockEarnings":[{"period":"1week","weight":-0.0333},{"period":"1month","weight":-0.0323},{"period":"3month","weight":-0.0773},{"period":"6month","weight":-0.0682},{"period":"1year","weight":0.4324},{"period":"ytd","weight":-0.0561}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0198},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0468},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.041}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10014人(较上一季度增加18.89%)","perCapita":"15716股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"15738万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是多肽原料药和制剂产品的研发、生产与销售,同时提供多肽创新药药学研究服务、多肽类产品定制生产服务以及左西孟旦制剂代加工和左西孟旦原料药生产与出口。公司的主要产品是醋酸奥曲肽注射液、注射用生长抑素、卡贝缩宫素注射液、醋酸阿托西班注射液、依替巴肽注射液、注射用胸腺法新、注射用胸腺五肽、注射用恩夫韦肽、艾替班特注射液、泊沙康唑注射液、醋酸加尼瑞克注射液、艾塞那肽注射液。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}